(Q40187951)

English

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study

scientific article published on 6 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 September 2017

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study (English)

1 reference

Europe PubMed Central

18 September 2017

gram-positive bacteria

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

object named as

Greg Moeck

4

0 references

author name string

G Ralph Corey

1

1 reference

Europe PubMed Central

18 September 2017

Samantha Good

2

1 reference

Europe PubMed Central

18 September 2017

Hai Jiang

3

1 reference

Europe PubMed Central

18 September 2017

Matthew Wikler

5

1 reference

Europe PubMed Central

18 September 2017

Sinikka Green

6

1 reference

Europe PubMed Central

18 September 2017

Paul Manos

7

1 reference

Europe PubMed Central

18 September 2017

Richard Keech

8

1 reference

Europe PubMed Central

18 September 2017

Rajesh Singh

9

1 reference

Europe PubMed Central

18 September 2017

Barry Heller

10

1 reference

Europe PubMed Central

18 September 2017

Natalia Bubnova

11

1 reference

Europe PubMed Central

18 September 2017

William O'Riordan

12

1 reference

Europe PubMed Central

18 September 2017

SOLO II Investigators

13

1 reference

Europe PubMed Central

18 September 2017

language of work or name

0 references

publication date

6 October 2014

1 reference

Europe PubMed Central

18 September 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

18 September 2017

60

1 reference

Europe PubMed Central

18 September 2017

2

1 reference

Europe PubMed Central

18 September 2017

254-262

1 reference

Europe PubMed Central

18 September 2017

Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Single-dose oritavancin in the treatment of acute bacterial skin infections.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU778

21 January 2018

Identifiers

10.1093/CID/CIU778

1 reference

Europe PubMed Central

18 September 2017

1 reference

Europe PubMed Central

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40187951&oldid=1888498065"